Unadjusted OR | 95% CI | Adjusted OR | 95% CI | P-value | |
---|---|---|---|---|---|
Adherence history: | |||||
poor at least once vs optimal | 2.14 | (1.45, 3.14) | 2.18 | (1.47, 3.22) | <0.001 |
non-response at least once vs optimal | 2.16 | (1.29, 3.52) | 2.09 | (1.22, 3.40) | <0.001 |
missing at least once vs optimal | 3.46 | (2.07, 5.54) | 3.65 | (2.15, 5.92) | 0.005 |
Pre-ART WHO disease stage | |||||
stage 2 | 1(ref) | 1(ref) | 0.51 | ||
stage 3 | 1.67 | (0.99, 3.03) | 1.39 | (0.82, 2.55) | |
stage 4 | 1.61 | (0.88, 3.08) | 1.28 | (0.68, 2.48) | |
Pre ART CD4 cell count | |||||
0-49 | 3.61 | (1.88, 7.85) | 3.43 | (1.74, 7.62) | |
50-99 | 2.75 | (1.36, 6.14) | 2.62 | (1.28, 5.90) | |
100-149 | 2.49 | (1.20, 5.63) | 2.45 | (1.18, 5.57) | |
150-199 | 1(ref) | 1(ref) | 0.01 | ||
Pre-ART Body mass index | |||||
<20 | 1.63 | (1.12, 2.38) | 1.33 | (0.90, 1.96) | |
20-27 | 1(ref) | 1(ref) | 0.35 | ||
>27 | 0.98 | (0.43, 1.93) | 1.07 | (0.46,2.15) | |
Age at ART initiation groups | |||||
18-35 | 1(ref) | 1(ref) | 0.07 | ||
35-50 | 0.72 | (0.49, 1.05) | 0.83 | (0.56, 1.24) | |
50+ | 1.45 | (0.74, 2.63) | 1.74 | (0.87, 3.21) | |
Sex | |||||
Female vs Male | 0.62 | (0.43, 0.90) | 0.72 | (0.49, 1.06) | 0.10 |
Time since ART initiation in years | |||||
≤2 | 1(ref) | 1(ref) | 0.13 | ||
2-3 | 1.65 | (0.98, 2.84) | 1.66 | (0.98, 2.86) | |
3-4 | 1.10 | (0.61, 1.99) | 1.10 | (0.61, 1.98) | |
4-5 | 1.64 | (0.96, 2.86) | 1.56 | (0.90, 2.74) | |
>5 | 0.91 | (0.38, 1.96) | 0.80 | (0.33, 1.73) |